| Literature DB >> 34899275 |
Jean-Christophe Perez1, Yannick N Gerber1, Florence E Perrin1,2.
Abstract
The glial scar that forms after traumatic spinal cord injury (SCI) is mostly composed of microglia, NG2 glia, and astrocytes and plays dual roles in pathophysiological processes induced by the injury. On one hand, the glial scar acts as a chemical and physical obstacle to spontaneous axonal regeneration, thus preventing functional recovery, and, on the other hand, it partly limits lesion extension. The complex activation pattern of glial cells is associated with cellular and molecular crosstalk and interactions with immune cells. Interestingly, response to SCI is diverse among species: from amphibians and fishes that display rather limited (if any) glial scarring to mammals that exhibit a well-identifiable scar. Additionally, kinetics of glial activation varies among species. In rodents, microglia become activated before astrocytes, and both glial cell populations undergo activation processes reflected amongst others by proliferation and migration toward the injury site. In primates, glial cell activation is delayed as compared to rodents. Here, we compare the spatial and temporal diversity of the glial response, following SCI amongst species. A better understanding of mechanisms underlying glial activation and scar formation is a prerequisite to develop timely glial cell-specific therapeutic strategies that aim to increase functional recovery.Entities:
Keywords: glial bridge; glial cells; glial scar; immune cells; primates; regenerative species; rodents; spinal cord injury (SCI)
Year: 2021 PMID: 34899275 PMCID: PMC8662749 DOI: 10.3389/fnagi.2021.769548
Source DB: PubMed Journal: Front Aging Neurosci ISSN: 1663-4365 Impact factor: 5.750
FIGURE 1Cellular dynamics after spinal cord injury. (A) Immune cell infiltration patterns in mice (plain lines) and rats (dashed lines). (B) Glial cell numbers in rodents (plain lines) and primates (dashed lines). For each cell type, both graphs represent the number of cells over time, relative to their maximum value.
FIGURE 2Glial scar formation after spinal cord injury in rodents and primates. (A) Acute stage. Cellular infiltration, reactivity, proliferation, and edema at the lesion site. (B) Glial scar stabilisation at the subacute/chronic stage. Note the substantial role of scarring astrocytes in separating the lesion core from spared tissues.
Studies demonstrating roles of the glial and immune cells after SCI in mice.
|
|
|
|
|
|
|
|
| |||||
| Contusion T9. 3, 7, 21, 28&42dys. IHC | CD11b MHCII | CD3,CD4, CD8 |
| ||
| HS T8. 8, 30, 90, 180&365dys: IHC | GFAP PSA NCAM | Isolectin B4 | NG2 |
| |
| Contusion T9. 3, 7, 14&42dys, IHC | Mac1, MHCII | LY6G,CD3, CD4, CD8 |
| ||
| Contusion T10-11. 15&45mns, 3&24hrs, 2&14dys | GFAP | Iba1, CD11b | CA2 | CD45 |
|
| Contusion T9-10. 3, 7&28dys. Microarrays, IHC | CD86, CD206, CD16, CD32, Arginase1 |
| |||
| Contusion T10-11. 3&12hrs, 4&28dys IHC, FACS | GFAP | Iba1. FACS: CD11b, CD45, CD16, CD32 | CA2 | 7/4, LY6B FACS: F480, LY6C, LY6G, |
|
| Contusion T9. 3, 7&49dys BrdU, IHC | GFAP BLBP | CD11b |
| ||
| Compression T5. 1, 3, 7, 14&42dys. | LY6G F480 Tg: LysM |
| |||
| Dorsal HS T9. 1, 4&54dys. Microarrays, BrdU | GFAP | CD11b | NG2 |
| |
| Dorsal section C4. 7dys&14wks TgFoxJ1, IHC | GFAP |
| |||
| Crush L1-2. 5, 14&28dys TgSTAT3KO, BrdU, IHC | Tg: GFAP GFAP Aquaporin4 BLBP, RC2 | CD45 | SOX2 |
| |
| Contusion T11. 24hrs, 3, 7, 14&42dys. IHC | Iba1, CD11b |
| |||
| Laser injury. 5, 30&120mins, FACS | Tg: CX3CR1 CD11+/Ly6C+ CD45 |
| |||
| HS T12. 30mins, 2, 8, 24, 48&72hrs. IHC | F480 |
| |||
| Contusion T8. 3, 5, 7, 14, 28&56dys. IHC | GFAP | Tg: CX3CR1 CD11b | Tg: LysM |
| |
| Crush T10. 2, 8&10wks RNAseq. Transgenic STAT3 KO, BrdU | Tg: GFAP GFAP | NG2 |
| ||
| Lateral crush T8. 3, 5, 7&14dys. | Tg: GFAP GFAP | CD11b | CC1 |
| |
| HS and FT T9. 1&2wks. FACS, RNA-seq, IHC | Tg: Aldh111 GFAP, FGFR4 |
| |||
| HS and FT T9. 72hrs, 1&2wks. FACS, RNA-seq, IHC | GFAP, Vim | Tg: CX3CR1 Iba1 |
| ||
| Crush and lateral stab T10. 2&8wks. Tg FoxJ1, BrdU, IHC | GFAP, Aldh111 |
| |||
| Contusion T8. 3&7dys. RNAseq, IHC | GFAP | Tg: LysM Tg:CD45, Tg: CD36 |
| ||
| Contusion T11. 1, 3, 4, 7&28dys. IHC. | CD11b, CD86, Iba1,P2RY12, TMEM119 | Tg: LysM Tg: CCR2 |
| ||
| Lateral contusion C5. 1, 3, 7, 11, 14&21dys, IHC | GFAP | Tg: NG2 ablation Olig2 |
| ||
| Contusion T9-10 1, 4, 7, 14&35dys, IHC | GFAP SOX9 | R26-TdT Tg: LysM Tg: CX3CR1cre CD68,P2RY12, |
| ||
| Crush T8. 2, 4&6wks Lentiviral-induced ablation, BrdU, IHC | Lv-GFAP to ablate astrocytes | Iba1 |
| ||
| Crush T10 3&7dys, 10wks,IHC, RNA-seq. | GFAP | CD68, P2Y12 RNA: CD11bTg: CX3CR1cre Tg: CSF1Rfl/fl |
| ||
FACS, flow cytometry; hrs, hours; min, minutes; dys, days; wks, weeks; mths, months; yrs, years; IHC, immunohistochemistry; C, cervical; T; thoracic; L, lumbar; HS, hemisection; FT, full transection; Tg, transgenic.
Studies demonstrating roles of the glial and immune cells after SCI in rats.
|
|
|
|
|
|
|
|
| |||||
| Partial section, 1, 3, 6, 12, 24hrs and 2, 4, 8, 14&12wks. IHC, HC | GFAP | CD11b, ED1 | Cresyl violet |
| |
| Contusion T8, 12, 72hrs, 7, 28dys IHC | GFAP | CD11b, ED1, MHCII | CD5 |
| |
| Stab dorsal 1&4mths | GFAP |
| |||
| Contusion T9, 3, 7, 21, 28&42dys IHC | CD11b, MHCII | CD4, CD8, CD11c |
| ||
| Contusion T8 1, 3&7dys, 6wks BrdU, IHC | GFAP | CD11b | NG2 CC1 |
| |
| Moderate contusion T8 3, 7, 28 &70dys | NG2 P75 P0 |
| |||
| Dorsal funiculotomy T8. 1hr, 10&30dys IHC | GFAP | CD11b ED1 CD68 | Olig2 |
| |
| Contusion T8 (3 severities) FACS: 0–10dys, 14, 90&180dys, IHC; 1, 7, 14&90dys | FACS:ED1, CD11b IHC: ED1 | FACS&IHCCD3, PME |
| ||
| Dorsal HS 3, 7, 14&28dys, IHC | ED1, CD8, CD86, CD206 | MPO, CD43 |
| ||
| ContusionT8 56dys, IHC | GFAP |
| |||
| FT T8 2, 8wks IHC | Morphology |
| |||
| FT T9 48hrs IHC | Nr3c1, ependymal glia is a Glcc target |
| |||
FACS, flow cytometry; hrs, hours; min, minutes; dys, days; wks, weeks; mths, months; yrs, years; IHC, immunohistochemistry; HC, histochemistry, H&E, hematoxylin eosin; C, cervical; T, thoracic; L, lumbar; HS, hemisection; FT, full transection.
Studies demonstrating roles of the glial and immune cells after SCI in primates.
|
|
|
|
|
|
|
|
| |||||
| 10wks, IHC | 3 contusion severities, C5 | GFAP |
| ||
| 1&4wks, IHC | Lateral HS, T8-9 | GFAP | OX42 |
| |
| 1hr, IHC | Balloon compression | GFAP | Iba1 |
| |
| 7&30dys, IHC | Lateral HS, T8-9 | GFAP | Iba1 CD68 |
| |
| 1, 2, 4&6wks, microarrays& RNA-seq. 1, 2&6wks, IHC | Contusion, C5 | GFAP | Iba1 |
| |
| 6mths, IHC | 2 contusion severities, T9 | GFAP |
| ||
| 12wks, IHC | lateral HS, T9-10 | GFAP | Iba1 |
| |
| 3mths, IHC | Lateral HS, T12-L1 | GFAP | Iba1 |
| |
| 3mths, IHC | Lateral HS, T12-L1 | GFAP | Iba1 |
| |
|
| |||||
| 27 cases, 5F&22M, 8–86 yrs | 8 dys-23yrs, IHC | Para- or tetraplegia C, T&L | GFAP |
| |
| 13 cases 21–85yrs | 2 dys- 30 yrs, IHC | Complete para- or tetraplegia C, T & L | GFAP |
| |
| 180 cases Ratio 5:1 M:F 8 mths to 92yrs | Instantaneous- 51yrs, IHC&HC | Predominantly C | GFAP | H&E |
|
| 11 cases, 2F & 9M 18–83yr | 30min - 19dys, IHC | Para or tetraplegia. | GFAP | MHCII |
|
| 1 case, 56yrs | 2yrs IHC | Complete C6 injury | GFAP |
| |
| 28 cases, 8F&20M, 6–88yrs | Instantaneous - 1yr, IHC | Contusion, compression&lacerationC1-T12. | CD68 |
| |
| 3 cases, 1F&2M, 49, 59 and 80yrs | 15, 20, 60 dys, IHC | Contusion, C | CD68 |
| |
| 1 case | 5dys, IHC | GFAP |
| ||
| 22 cases, 6F&16M 15–80yrs | <1–413 dys, IHC | T & C | IBA1 | TMEM119 P2RY12 |
|
hrs, hours; min, minutes; dys, days; wks, weeks; mths, months; yrs, years; IHC, immunohistochemistry; HC, histochemistry; H&E, hematoxylin eosin; M, male; F, female; C, cervical; T, thoracic; L, lumbar; HS, hemisection.
FIGURE 3The glial bridge after spinal cord injury in species with high regenerative capacities and perinatal mammals. (A) Tissue clearance, glial bridge, and axon sprouting at the acute/subacute stage. Arrows represent the involvement of radial glia in the glial bridge formation. (B) Remyelination and return to homeostasis at the chronic stage.
Studies demonstrating roles of the glial and immune cells after SCI in species with high regenerative capacities.
|
|
|
|
|
|
|
|
| |||||
| Rats: Adults | GFAP | OX42 |
| ||
| Zebra larvae 5dpf. FT. ISH, IH | GFAP | Tg Dbx1a, | Tg olig2 |
| |
| Rats: Adult | GFAP |
| |||
| Zebra larvae. 2dpf Mechanical lesion. IHC | L-Plastin 4C4 | Tg olig2 |
| ||
| Zebra larvae. FT. ISH, IHC. | Tg: | TgMpx |
| ||
| Zebra larvae. FT. BrdU. | Tg mpeg | Tg: Mpx olig2 |
| ||
| Neonate rats Zebra larvae. 3dpf. Dexamethasone FT.6, 24, 48, 72&120 hrs | Tg |
| |||
| Neonate mice P2. Crush. ISH, IHC, RNAseq | GFAP | CX3CR1 Csf1r |
| ||
| Vimentin BLBP GS |
| ||||
| Zebra larvae. 3dpf. Stab injury. 12hrs. FACS, RNAseq. IHC. | Tg GFAP | SOX2 NG2 |
| ||
|
| |||||
| GFAP |
| ||||
| Zebrafish, FT. IHC, EM | 4C4 |
| |||
| Newts (Salamander), FT. 1&3 dys; 1, 2, 3, 6&9 wks. IHC, HC, EM. | GFAP |
| |||
| Zebrafish, FT. BrdU, IHC | GFAP, vimentin |
| |||
| Zebrafish, FT.IHC, ISH, tissue clearing, EdU | GFAP | Tg(olig2:eGFP |
| ||
FACS, flow cytometry; hrs, hours; dys, days; wks, weeks; IHC, immunohistochemistry; T, thoracic; L, lumbar; FT, full transection; EM, electronic microscopy; ISH,